AtriCure (ATRC) director Maggie Yuen receives 6,144-share restricted stock award

Rhea-AI Filing Summary

AtriCure, Inc. director Maggie Yuen reported receiving a grant of common stock as equity compensation. She was awarded 6,144 shares of Common Stock on May 18, 2026 at a stated price of $0.00 per share under the AtriCure, Inc. 2023 Stock Incentive Plan.

The award is structured as restricted stock and will vest on the one-year anniversary of the grant date. Following this grant, Yuen directly holds 17,515 shares of AtriCure common stock. This filing reflects a compensation-related acquisition rather than an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Yuen Maggie

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	6,144	$0.00	--

Holdings After Transaction: Common Stock — 17,515 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Restricted stock grant: 6,144 shares Grant price: $0.00 per share Post-grant holdings: 17,515 shares +1 more

4 metrics

Restricted stock grant 6,144 shares Common Stock awarded May 18, 2026

Grant price $0.00 per share Restricted Stock Award under 2023 Stock Incentive Plan

Post-grant holdings 17,515 shares Total common shares directly owned after grant

Vesting period One year Shares vest on one-year anniversary of grant date

Key Terms

Restricted Stock Award, 2023 Stock Incentive Plan, transaction code "A", Form 4

4 terms

Restricted Stock Award financial

"The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan."

A restricted stock award is company shares given to an employee or executive that cannot be sold or fully owned until certain conditions—like staying with the company for a set time or hitting performance targets—are met. Think of it as a gift that only becomes yours after you fulfill specific obligations; for investors, these awards matter because they can increase the total shares outstanding when they vest, reveal how management is being paid and motivated, and create potential selling pressure when restrictions lift.

2023 Stock Incentive Plan financial

"Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan."

transaction code "A" regulatory

"transaction_code": "A","transaction_code_description": "Grant, award, or other acquisition""

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yuen Maggie

(Last) (First) (Middle)

7555 INNOVATION WAY

(Street)

MASON OHIO 45040-9695

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/18/2026		A		6,144(1)	A	$0	17,515	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

Remarks:

	/s/ Allison Walker as Attorney-in-fact for Maggie Yuen	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did AtriCure (ATRC) director Maggie Yuen report?

Director Maggie Yuen reported receiving a grant of 6,144 shares of AtriCure common stock. The award is part of her equity compensation and was issued under the company’s 2023 Stock Incentive Plan, rather than through an open-market purchase.

How many AtriCure (ATRC) shares were granted to Maggie Yuen and at what price?

Maggie Yuen was granted 6,144 shares of AtriCure common stock at a stated price of $0.00 per share. This reflects a restricted stock award, a common form of non-cash director compensation, rather than a cash purchase in the market.

When do Maggie Yuen’s newly granted AtriCure (ATRC) shares vest?

The 6,144 restricted shares granted to Maggie Yuen will vest on the one-year anniversary of the grant date. Until vesting, the shares are subject to the award’s restrictions under AtriCure’s 2023 Stock Incentive Plan.

What is Maggie Yuen’s AtriCure (ATRC) share ownership after this Form 4?

After this restricted stock grant, Maggie Yuen directly owns 17,515 shares of AtriCure common stock. This total includes the newly awarded 6,144 shares reported in the Form 4 insider trading report.

Is the AtriCure (ATRC) Form 4 transaction a market buy or compensation grant?

The Form 4 shows a compensation grant, not a market buy. The transaction code "A" and the $0.00 per share price indicate a restricted stock award given under AtriCure’s 2023 Stock Incentive Plan to director Maggie Yuen.